Urogen Pharma (NASDAQ:URGN) Earns "Buy" Rating from D. Boral Capital

Key Points

• D. Boral Capital has reaffirmed a "buy" rating for Urogen Pharma (NASDAQ:URGN) with a target price of **$25.00**, indicating a potential upside of **46.46%** from the stock's previous close.
• Urogen Pharma's stock recently reported a **4.2% decline**, with current trading at **$17.07** and an average rating of "buy" among analysts, who have set a consensus target price of **$32.00**.
• The company reported a quarterly loss of **($1.05) EPS**, missing estimates by **($0.23)**, while its revenue was **$24.22 million**, exceeding analyst expectations.

Urogen Pharma (NASDAQ:URGN - Get Free Report)'s stock had its "buy" rating restated by investment analysts at D. Boral Capital in a report released on Friday,Benzinga reports. They presently have a $25.00 price objective on the stock. D. Boral Capital's target price points to a potential upside of 46.46% from the company's previous close.

Several other brokerages also recently weighed in on URGN. HC Wainwright decreased their target price on shares of Urogen Pharma from $50.00 to $40.00 and set a "buy" rating for the company in a research note on Monday, August 11th. Piper Sandler assumed coverage on Urogen Pharma in a research note on Monday, August 18th. They set an "overweight" rating and a $36.00 target price for the company. Oppenheimer set a $31.00 price objective on shares of Urogen Pharma and gave the company a "buy" rating in a research note on Friday, June 13th. Guggenheim restated a "buy" rating and issued a $30.00 price target (up previously from $15.00) on shares of Urogen Pharma in a report on Friday, June 13th. Finally, The Goldman Sachs Group set a $16.00 price target on Urogen Pharma and gave the stock a "neutral" rating in a research note on Friday, June 13th. One equities research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and one has assigned a Hold rating to the company's stock. According to MarketBeat, Urogen Pharma currently has an average rating of "Buy" and a consensus target price of $32.00.

Urogen Pharma Stock Down 4.2%

Shares of URGN opened at $17.07 on Friday. The company has a market capitalization of $789.66 million, a price-to-earnings ratio of -5.14 and a beta of 1.00. Urogen Pharma has a 52-week low of $3.42 and a 52-week high of $21.71. The stock has a 50 day moving average price of $19.03 and a 200 day moving average price of $13.63.

Urogen Pharma (NASDAQ:URGN - Get Free Report) last announced its quarterly earnings results on Thursday, August 7th. The company reported ($1.05) EPS for the quarter, missing the consensus estimate of ($0.82) by ($0.23). Urogen Pharma had a negative return on equity of 97,487.15% and a negative net margin of 164.44%.The company had revenue of $24.22 million for the quarter, compared to analyst estimates of $23.06 million. On average, equities analysts anticipate that Urogen Pharma will post -3.12 EPS for the current fiscal year.

Insider Activity

In other news, General Counsel Jason Drew Smith sold 7,522 shares of the firm's stock in a transaction that occurred on Monday, July 28th. The shares were sold at an average price of $19.14, for a total transaction of $143,971.08. Following the completion of the sale, the general counsel owned 41,492 shares of the company's stock, valued at approximately $794,156.88. This trade represents a 15.35% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Mark Schoenberg sold 10,000 shares of the business's stock in a transaction dated Monday, August 11th. The shares were sold at an average price of $17.69, for a total value of $176,900.00. Following the completion of the sale, the insider directly owned 148,229 shares of the company's stock, valued at approximately $2,622,171.01. This represents a 6.32% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 25,062 shares of company stock worth $465,115. Insiders own 4.70% of the company's stock.

Hedge Funds Weigh In On Urogen Pharma

Large investors have recently made changes to their positions in the business. Nuveen LLC bought a new stake in shares of Urogen Pharma during the 1st quarter worth $1,028,000. Rhumbline Advisers increased its holdings in shares of Urogen Pharma by 4.3% in the 1st quarter. Rhumbline Advisers now owns 53,466 shares of the company's stock valued at $591,000 after purchasing an additional 2,196 shares during the period. Persistent Asset Partners Ltd purchased a new stake in Urogen Pharma in the 1st quarter worth approximately $194,000. Parkman Healthcare Partners LLC boosted its position in Urogen Pharma by 6.3% during the first quarter. Parkman Healthcare Partners LLC now owns 393,153 shares of the company's stock valued at $4,348,000 after purchasing an additional 23,292 shares during the last quarter. Finally, XTX Topco Ltd grew its stake in shares of Urogen Pharma by 39.3% in the 1st quarter. XTX Topco Ltd now owns 25,967 shares of the company's stock valued at $287,000 after buying an additional 7,326 shares in the last quarter. Institutional investors own 91.29% of the company's stock.

Urogen Pharma Company Profile

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.